“Patient Preference for Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Foam or Topical Suspension Vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S10, https://doi.org/10.25251/skin.2.supp.10.